読み込み中
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
前日終値
$1.72
−$0.21 · -10.88%
日中の時刻はETです。市場データは遅延する場合があります。
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
日中レンジ
現在 $1.72
52週レンジ
現在 $1.72
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
47
適正価値
センチメント
68
強気
リスク
66
高リスク
モメンタム
29
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
日中レンジ
現在 $1.72
52週レンジ
現在 $1.72
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 197.67万 USD | 1119.81万 USD | −285.08万 USD | 50万 USD | 1614.08万 USD |
| 売上原価 | 858.39万 USD | — | 1017.53万 USD | 855.69万 USD | 766.56万 USD |
| 粗利益 | −660.72万 USD | 1119.81万 USD | −1302.61万 USD | −805.69万 USD | 847.53万 USD |
| 研究開発 | — | 735.18万 USD | — | — | — |
| 販売・一般管理 | 376.41万 USD | 500.14万 USD | 490.49万 USD | 406.25万 USD | 532.98万 USD |
| 営業費用 | 376.41万 USD | 1235.32万 USD | 490.49万 USD | 406.25万 USD | 532.98万 USD |
| 受取利息 | 74.41万 USD | 114.69万 USD | 136.69万 USD | 57.26万 USD | 6.77万 USD |
| 支払利息 | — | — | — | 2.71万 USD | 20.33万 USD |
| 減価償却費と償却費 | 6.08万 USD | 4.11万 USD | 2.87万 USD | 9453 USD | 380 USD |
| 営業利益 | −1037.14万 USD | −115.5万 USD | −1793.1万 USD | −1211.94万 USD | 314.55万 USD |
| 純利益 | −962.75万 USD | 8352 USD | −1635.21万 USD | −1075.86万 USD | −63.44万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$5.00
上昇余地（190.70%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2023年5月12日 | 1:17 | — | — |
発効済み 2023年5月12日
1:17
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI31.98万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF19.72万0.00%954億 USD0.05%$235+0.80%
Dimensional - US Small Cap ETFDFAS1.17万0.00%338.69億 USD0.31%$78.35+0.32%
Dimensional - US Sustainability Core 1 ETFDFSU9997.40.00%23.92億 USD0.15%$48.11+0.48%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR9873.880.00%455.91億 USD0.17%$84.44+0.44%
U.S. Micro Cap Portfolio ETFDFMC9727.20.00%75.58億 USD0.43%$57.813+0.20%
Dimensional - US Core Equity 2 ETFDFAC9248.560.00%885.96億 USD0.21%$45.33+0.49%
U.S. Vector Equity Portfolio ETF Class SharesDXUV4161.080.00%61.81億 USD0.26%$68.28+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORU.S. Micro Cap Portfolio ETFDFMCDimensional - US Core Equity 2 ETFDFACU.S. Vector Equity Portfolio ETF Class SharesDXUVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
